Last 33 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -75.41 | 403.63 | — | — | — | 255.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +57.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 15.28 | 16.09 | 11.82 | 7.61 | 8.67 | 25.97 | 30.09 | 21.14 | 18.60 | 16.27 | 12.36 | 11.18 | 15.51 | 5.20 | 4.95 | 8.42 | 4.95 | 5.32 | 6.59 | 12.73 | 26.12 |
| — | -38.0% | -60.7% | -64.0% | -53.4% | +59.7% | +143.5% | +89.1% | +19.9% | +212.8% | +149.6% | +32.8% | +213.3% | -2.2% | -24.9% | -33.9% | -81.0% | -82.5% | -82.3% | -65.0% | -61.1% | |
| P/B Ratio | 19.19 | 29.37 | 22.45 | 9.63 | 11.05 | 47.80 | 39.47 | 23.31 | 17.44 | 13.51 | 8.84 | 6.81 | 9.21 | 2.18 | 2.45 | 2.99 | 2.35 | 2.09 | 2.22 | 3.55 | 6.56 |
| — | -38.6% | -43.1% | -58.7% | -36.6% | +253.7% | +346.5% | +242.2% | +89.3% | +519.6% | +261.3% | +127.9% | +291.2% | +4.5% | +10.1% | -15.9% | -64.1% | -71.6% | -73.1% | -53.9% | -39.8% | |
| P/FCF | — | 175.90 | — | — | 438.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 455.24 | — | — | — | 166.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +173.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | 195.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.2% | 76.2% | 71.2% | 73.6% | 74.6% | 80.7% | 69.4% | 67.6% | 62.0% | 64.1% | 55.3% | 56.9% | 57.2% | 49.0% | 63.4% | 50.4% | 69.9% | 68.8% | 69.7% | 65.8% | 62.2% |
| — | -5.5% | +2.6% | +8.8% | +20.3% | +25.9% | +25.6% | +18.9% | +8.4% | +30.9% | -12.8% | +12.9% | -18.3% | -28.8% | -9.1% | -23.5% | +12.5% | +7.5% | -3.2% | -11.0% | -21.7% | |
| Operating Margin | -20.6% | -0.5% | -22.0% | -27.1% | -17.8% | 10.9% | -42.5% | -56.4% | -71.3% | -70.3% | -109.6% | -116.5% | -155.2% | -134.4% | -97.7% | -151.9% | -71.0% | -95.0% | -120.3% | -163.3% | -162.4% |
| — | -105.0% | +48.2% | +52.0% | +75.0% | +115.6% | +61.2% | +51.5% | +54.1% | +47.7% | -12.1% | +23.3% | -118.7% | -41.5% | +18.7% | +7.0% | +56.3% | +33.4% | +7.0% | -52.1% | -10.8% | |
| Net Margin | -21.5% | 3.4% | -55.6% | -28.3% | -18.9% | 10.2% | -43.5% | -56.9% | -71.0% | -69.1% | -107.0% | -113.5% | -151.7% | -132.7% | -97.7% | -153.3% | -72.7% | -94.7% | -119.2% | -162.6% | -161.7% |
| — | -66.3% | -27.8% | +50.3% | +73.3% | +114.7% | +59.4% | +49.8% | +53.2% | +47.9% | -9.5% | +26.0% | -108.6% | -40.1% | +18.0% | +5.7% | +55.0% | +33.2% | +6.9% | -53.8% | -9.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.8% | 1.7% | -21.2% | -8.9% | -6.3% | 5.0% | -13.9% | -15.2% | -15.8% | -13.8% | -17.9% | -16.3% | -20.7% | -13.3% | -11.7% | -13.0% | -8.4% | -9.0% | -9.7% | -10.9% | -9.8% |
| — | -65.4% | -53.2% | +41.3% | +60.0% | +136.1% | +22.6% | +6.7% | +23.7% | -3.9% | -53.6% | -25.4% | -145.9% | -47.5% | -20.1% | -19.7% | +13.7% | -8.3% | -39.8% | -96.1% | -66.4% | |
| ROA | -11.3% | 0.4% | -6.9% | -3.9% | -2.7% | 1.9% | -5.1% | -5.7% | -6.1% | -5.6% | -7.7% | -7.4% | -10.1% | -6.8% | -6.1% | -7.0% | -4.6% | -5.4% | -6.3% | -7.0% | -6.4% |
| — | -77.5% | -36.5% | +30.8% | +55.9% | +134.5% | +33.7% | +23.3% | +39.1% | +17.3% | -24.8% | -5.9% | -118.5% | -26.7% | +1.7% | +0.7% | +28.0% | +2.9% | -33.5% | -89.8% | -58.9% | |
| ROIC | -12.6% | -0.1% | -3.2% | -3.6% | -2.9% | 3.4% | -8.4% | -9.4% | -9.7% | -8.8% | -12.3% | -11.4% | -14.9% | -10.0% | -8.7% | -9.4% | -6.8% | -7.3% | -7.1% | -8.4% | -7.6% |
| — | -102.2% | +62.2% | +61.4% | +70.5% | +138.6% | +31.9% | +17.1% | +34.6% | +11.5% | -41.8% | -21.8% | -118.1% | -36.8% | -22.0% | -11.6% | +10.0% | -9.0% | -21.2% | -86.7% | -20.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.25 | 2.22 | 2.72 | 0.93 | 1.25 | 0.40 | 0.47 | 0.46 | 0.44 | 0.41 | 0.39 | 0.35 | 0.32 | 0.28 | 0.26 | 0.25 | 0.23 | 0.22 | 0.21 | 0.21 | 0.18 |
| — | +455.3% | +479.8% | +103.2% | +182.5% | -2.5% | +20.5% | +30.1% | +37.8% | +46.6% | +49.2% | +40.7% | +37.7% | +25.3% | +21.7% | +21.6% | +25.8% | +28.7% | +37.1% | +49.6% | +27.5% | |
| Debt / EBITDA | — | 129.87 | — | — | — | 5.57 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +2233.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.34 | 3.97 | 4.79 | 3.35 | 3.34 | 3.38 | 2.84 | 2.92 | 2.89 | 3.52 | 3.99 | 4.51 | 4.66 | 4.67 | 5.00 | 5.56 | 5.12 | 5.43 | 3.93 | 3.64 | 3.54 |
| — | +17.5% | +68.7% | +14.8% | +15.4% | -4.1% | -28.8% | -35.2% | -37.9% | -24.6% | -20.2% | -19.0% | -9.0% | -14.0% | +27.1% | +52.8% | +44.7% | +42.2% | -28.7% | -49.2% | -48.8% | |
| Quick Ratio | 3.23 | 3.87 | 4.68 | 3.22 | 3.23 | 3.26 | 2.75 | 2.82 | 2.81 | 3.38 | 3.84 | 4.35 | 4.50 | 4.46 | 4.80 | 5.34 | 4.99 | 5.26 | 3.77 | 3.46 | 3.37 |
| — | +18.7% | +70.0% | +14.3% | +15.0% | -3.7% | -28.4% | -35.1% | -37.6% | -24.1% | -20.1% | -18.6% | -9.9% | -15.3% | +27.5% | +54.4% | +48.0% | +43.4% | -29.7% | -50.6% | -50.3% | |
| Interest Coverage | -4.05 | -0.91 | -5.85 | -6.31 | -3.60 | 4.21 | -7.68 | -11.28 | -10.42 | -9.92 | -16.15 | -14.88 | -22.06 | -12.78 | -12.26 | -15.34 | -10.20 | -68.40 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADPT stock.
Adaptive Biotechnologies Corporation's current P/E is -75.4x. The average P/E over the last 1 quarters is 403.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Adaptive Biotechnologies Corporation's current operating margin is -20.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Adaptive Biotechnologies Corporation's business trajectory between earnings reports.